Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 34
Filter
5.
Acta Derm Venereol ; 99(7): 664-667, 2019 Jun 01.
Article in English | MEDLINE | ID: mdl-30848285

ABSTRACT

Pityriasis rosea is a common acute exanthema of unknown aetiology, which causes severe anxiety. In this study, the demographic data of pityriasis rosea patients, who presented to our clinic between 2013 and 2017, were prospectively recorded. The patients with a confirmed pityriasis rosea diagnosis were followed up for 4 years in order to investigate the recurrence rate. Of the clinically suspected patients, having a typical history of pityriasis rosea manifestations, a herald patch, and/or secondary coloured squamous lesions, 400 were confirmed by biopsy to have pityriasis rosea. The 4-year follow-up was completed in 212 patients, of whom 136 (64.2%) were female and 76 (35.8%) were male. The recurrence rate was determined as 25.9% at the end of the 4-year follow-up period.


Subject(s)
Pityriasis Rosea/complications , Pityriasis Rosea/pathology , Pruritus/etiology , Adult , Biopsy , Female , Follow-Up Studies , Humans , Hypersensitivity/complications , Male , Prospective Studies , Recurrence , Severity of Illness Index , Skin/pathology , Time Factors
7.
Rev. chil. obstet. ginecol. (En línea) ; 83(4): 386-393, 2018. tab, graf, ilus
Article in Spanish | LILACS | ID: biblio-978110

ABSTRACT

RESUMEN A pesar de que la Pitiriasis Rosada se considera una condición cutánea benigna, en el marco del embarazo, hay estudios que relacionan la aparición de esta patología con complicaciones asociadas en el feto. Metodología: Se realiza un reporte de caso, prospectivo, a una mujer de 36 años chilena que presentó esta patología durante la semana 12 de gestación. El objetivo fue describir, la evolución y control y contrastar su evolución con la evidencia científica actual sobre esta temática. Resultados: Paciente presenta placas eritematodescamativas concordantes con diagnóstico de pitiriasis rosada (superficie afectada menos al 50% de su cuerpo), sin presentar enantema, ni síntomas sistémicos. Tuvo un recién nacido sano a las 38 semanas de gestación, sin presentar ningún efecto adverso de los que relaciona la literatura analizada. Conclusiones: Distintos estudios han estudiado los posibles efectos adversos en el feto en madres que han presentado Pitiriasis Rosada en el embarazo, sin embargo, en este reporte de caso no se presentaron complicaciones asociadas. Faltan estudios realizados en mayor cantidad de pacientes.


ABSTRACT Although Pityriasis Rosea is considered a benign cutaneous condition, in the context of pregnancy, there are studies that relate the appearance of this pathology with associated complications in the fetus. Methodology: A prospective case report was made to a 36-year-old Chilean woman who presented this pathology during the twelve weeks of pregnancy. The objective was to describe, the evolution and control and to contrast its evolution with the current scientific evidence on this subject. Results: Patient presents concordant erythematous-desquamative plaques with diagnosis of Pityriasis Rosea (surface affected less than 50% of his body), without presenting enanthem, nor systemic symptoms. Had a healthy newborn at 38 weeks of gestation, without presenting any adverse effect related to the analyzed literature. Conclusions: Different studies have studied the possible adverse effects on the fetus in mothers who have presented pityriasis rosea in pregnancy, however in this case report there were no associated complications. Missing studies in a greater number of patients.


Subject(s)
Humans , Female , Pregnancy , Infant, Newborn , Adult , Pityriasis Rosea/complications , Pityriasis Rosea/diagnosis , Pityriasis Rosea/prevention & control , Pregnancy Complications , Pityriasis Rosea/pathology , Pityriasis Rosea/virology , Herpesvirus 6, Human/isolation & purification , Herpesvirus 7, Human/isolation & purification
8.
Dermatol Online J ; 23(2)2017 Feb 15.
Article in English | MEDLINE | ID: mdl-28329497

ABSTRACT

Pityriasis Rosea (PR) is a common skin disorderencountered in daily practice. Although its etiologyhas not been established, there has been widespreadresearch into possibilities. The lack of its characteristicmanifestations, specifically the herald patch andtruncal involvement, can lead to pitfalls in diagnosis.Whereas other conditions in the differential diagnosisshould be considered, PR can at times also manifest inan atypical manner. We wish to illustrate three casesof PR including those that presented with aphthousulcers, vesicles, and an inverse pattern.


Subject(s)
Pityriasis Rosea/diagnosis , Skin Diseases, Vesiculobullous/diagnosis , Stomatitis, Aphthous/diagnosis , Administration, Cutaneous , Administration, Oral , Adrenal Cortex Hormones/therapeutic use , Antiviral Agents/therapeutic use , Emollients/therapeutic use , Histamine Antagonists/therapeutic use , Humans , Pityriasis Rosea/complications , Pityriasis Rosea/therapy , Skin Diseases, Vesiculobullous/etiology , Skin Diseases, Vesiculobullous/therapy , Stomatitis, Aphthous/etiology , Stomatitis, Aphthous/therapy , Ultraviolet Therapy
9.
BMJ Case Rep ; 20172017 Jan 23.
Article in English | MEDLINE | ID: mdl-28115404

ABSTRACT

Pityriasis rosea is a dermatological disease with a well-documented clinical appearance, but less is known about causes and treatment. Bell's palsy is a neurological condition leading to acute idiopathic hemifacial paralysis. Recent studies indicate that human herpesvirus (HHV) 6-7 reactivation may be a contributing factor to both conditions. We report a case of the 2 concurrent diagnoses that supports a common contributing factor and suggests further awareness and research into the role HHV 6-7 may play in the aetiology of both conditions.


Subject(s)
Bell Palsy/complications , Pityriasis Rosea/complications , Roseolovirus Infections/complications , Acyclovir/therapeutic use , Antiviral Agents/therapeutic use , Bell Palsy/drug therapy , Bell Palsy/virology , Child , Female , Glucocorticoids/therapeutic use , Herpesvirus 6, Human , Herpesvirus 7, Human , Humans , Pityriasis Rosea/drug therapy , Pityriasis Rosea/virology , Prednisone/therapeutic use , Roseolovirus Infections/drug therapy , Roseolovirus Infections/virology
11.
Curr Probl Dermatol ; 50: 173-91, 2016.
Article in English | MEDLINE | ID: mdl-27578087

ABSTRACT

Itch in children is a very common symptom and is mainly related to a skin disease rather than an underlying systemic disorder. The most common dermatoses include atopic dermatitis, contact dermatitis, insect bites, scabies, and pediculosis capitis. There are specific diagnostic patterns which require the evaluation of a careful history and dermatological examination. For dermatological treatment, we have to consider that children, especially infants, show differences in physiology and pathophysiology, and also in pharmacokinetics and pharmacodynamics compared with adults.


Subject(s)
Antipruritics/therapeutic use , Histamine Antagonists/therapeutic use , Pruritus/therapy , Acrodermatitis/complications , Acrodermatitis/therapy , Chickenpox/complications , Chickenpox/therapy , Child , Child, Preschool , Dermatitis, Atopic/complications , Dermatitis, Atopic/therapy , Dermatitis, Contact/complications , Dermatitis, Contact/therapy , Epidermolysis Bullosa/complications , Epidermolysis Bullosa/therapy , Exanthema/complications , Exanthema/therapy , Humans , Infant , Insect Bites and Stings/complications , Insecticides/therapeutic use , Lice Infestations/complications , Lice Infestations/drug therapy , Mastocytosis/complications , Mastocytosis/drug therapy , Neurofibromatosis 1/complications , Neurofibromatosis 1/therapy , Permethrin/therapeutic use , Pityriasis Rosea/complications , Pityriasis Rosea/therapy , Pruritus/etiology , Scabies/complications , Scabies/drug therapy , Scalp Dermatoses/complications , Scalp Dermatoses/drug therapy , Skin Care
12.
A A Case Rep ; 7(8): 165-168, 2016 Oct 15.
Article in English | MEDLINE | ID: mdl-27513966

ABSTRACT

Pityriasis rosea (PR) is an acute exanthematous skin disease that is likely due to reactivation of human herpesviruses (HHVs) 6b and 7. In contrast to herpes simplex and zoster (alphaherpesviruses), HHV-6b and -7 (betaherpesviruses) are not found predominantly in skin lesions. This difference in virion location may decrease the possibility of causing central nervous system infection through skin contamination, but the risk for hematogenous spread likely remains the same. This article uses the first-known epidural placement through active PR to illustrate risk-benefit considerations when deciding between neuraxial and general anesthesia for obstetric patients with PR.


Subject(s)
Anesthesia, Epidural/methods , Anesthesia, Obstetrical/methods , Cesarean Section, Repeat/methods , Lumbar Vertebrae , Pityriasis Rosea/diagnosis , Pregnancy Complications/diagnosis , Adult , Female , Humans , Pityriasis Rosea/complications , Pityriasis Rosea/surgery , Pregnancy , Pregnancy Complications/surgery
15.
Dermatology ; 230(1): 23-6, 2015.
Article in English | MEDLINE | ID: mdl-25612842

ABSTRACT

Pityriasis rosea (PR) is an acute, self-limiting exanthematous disease, associated with the reactivation of the human herpesvirus 6 (HHV-6) and/or human herpesvirus 7 (HHV-7) that usually lasts 6-8 weeks. We studied, from a clinical and virological point of view, 12 patients in whom the features of PR lasted longer than 12 weeks, defining this form of the disease as persistent PR (PPR). As in typical PR, in most of the PPR patients the disease begins with a herald patch, but compared to typical PR, systemic symptoms and oral lesions are more common. Moreover, in PPR we found a persistent reactivation of HHV-6 and/or HHV-7 with higher viral loads than in typical PR, accounting for the unusual persistence of the illness, the more frequent and severer systemic symptoms and the oral lesions. In conclusion, we describe an unusual persistent form of PR, whose prevalence has probably been underestimated so far and which should be added to the other variants of PR.


Subject(s)
Herpesviridae Infections/immunology , Herpesvirus 6, Human/immunology , Herpesvirus 7, Human/immunology , Pityriasis Rosea/virology , Adult , Female , Herpesviridae Infections/complications , Herpesviridae Infections/virology , Humans , Male , Pityriasis Rosea/complications , Pityriasis Rosea/immunology , Viral Load , Young Adult
18.
Article in English | MEDLINE | ID: mdl-24448121

ABSTRACT

BACKGROUND: Macrolides are prescribed in the treatment of pityriasis rosea despite conflicting results of the limited number of studies evaluating their role in its treatment. AIM: A randomized double-blind placebo-controlled trial was conducted to evaluate the effect of azithromycin on the clinical course of pityriasis rosea. METHODS: Seventy patients of pityriasis rosea were given either azithromycin (n=35) or placebo (n=35) and were followed-up at 2, 4 and 6 weeks. Pruritus was assessed in both groups using the visual analogue scale (VAS) . Change in the pityriasis rosea severity score (PRSS) and in the VAS were recorded as outcome measures and were compared statistically. RESULTS: The decrease in PRSS from baseline through 2, 4 and 6 weeks within both treatment (P<0.001) and placebo (P<0.001) arms was found to be statistically significant; however, this change was not significantly different in the two groups (P=0.179). Similarly, the decrease in VAS was found to be statistically significant within both groups (P<0.001); however, the change was comparable between the two groups (P<0.937). Analysis by Fisher's exact test did not find a significant difference between the two groups for PRSS and VAS. CONCLUSION: Azithromycin is not effective in pityriasis rosea and the use of macrolides for this disease should not be encouraged in clinical practice.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Azithromycin/therapeutic use , Pityriasis Rosea/drug therapy , Adolescent , Adult , Double-Blind Method , Female , Humans , Male , Pityriasis Rosea/complications , Prospective Studies , Pruritus/etiology , Severity of Illness Index , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...